Cue Biopharma (CUE) — Financial Flexibility Index
Cue Biopharma (CUE) has a Financial Flexibility Index of -0.49x as of September 2025. Free cash flow of $-9.02 Million (operating CF $-9.02 Million minus capex $0.00) represents 0% of total liabilities ($18.40 Million). Check tangible equity quality of Cue Biopharma to evaluate the tangible quality of the company's equity base.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Cue Biopharma Financial Flexibility Index (2015–2024)
Historical Financial Flexibility Index trend for Cue Biopharma across 10 annual periods. For the full cash flow conversion analysis, see CUE operating cash flow.
Annual Financial Flexibility Index for Cue Biopharma (2015–2024)
Year-by-year free cash flow to debt coverage for Cue Biopharma. Explore Cue Biopharma cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -2.47x | $-36.26 Million | $-36.33 Million | $14.69 Million | ▼ -51.0% |
| 2023 | -1.63x | $-39.96 Million | $-39.96 Million | $24.45 Million | ▼ -0.5% |
| 2022 | -1.63x | $-41.63 Million | $-41.81 Million | $25.60 Million | ▲ +23.2% |
| 2021 | -2.12x | $-37.92 Million | $-38.84 Million | $17.91 Million | ▼ -36.9% |
| 2020 | -1.55x | $-31.90 Million | $-32.49 Million | $20.62 Million | ▲ +14.4% |
| 2019 | -1.81x | $-30.75 Million | $-30.80 Million | $17.02 Million | ▲ +16.2% |
| 2018 | -2.16x | $-24.56 Million | $-26.41 Million | $11.39 Million | ▼ -4.9% |
| 2017 | -2.05x | $-10.99 Million | $-12.19 Million | $5.35 Million | ▲ +58.4% |
| 2016 | -4.94x | $-5.45 Million | $-5.97 Million | $1.10 Million | ▼ -105.7% |
| 2015 | -2.40x | $-903.28K | $-1.66 Million | $376.30K | — |